Actively Recruiting
Predicting Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma
Led by City of Hope Medical Center · Updated on 2025-07-11
150
Participants Needed
2
Research Sites
1067 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The prognosis of patients with esophageal squamous cell carcinoma (ESCC) who develop post-operative early tumor recurrence is often relatively poor. Therefore, biomarker that can detect micro metastases before the start of treatment is required. Epigenomic alterations such as DNA methylation have attracted attention as promising biomarkers. The investigators aim to predict early recurrence based on whole genome DNA methylation analysis of esophageal cancer.
CONDITIONS
Official Title
Predicting Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed esophageal squamous cell carcinoma (ESCC)
- Complete esophagectomy with radical lymph node dissection without chemotherapy or radiotherapy before or after surgery
- Availability of tissue samples from surgery
- Complete follow-up with observation periods of at least 2 years after surgery
- Written informed consent provided after full study information
You will not qualify if you...
- Lack of clinical information within 2 years after surgery
- Presence of multiple cancers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Nagoya University
Nagoya, Aichi-ken, Japan, 4668560
Actively Recruiting
2
Yamanashi Universiy
Chūō, Yamanashi, Japan, 4093898
Actively Recruiting
Research Team
A
Ajay Goel, PhD
CONTACT
K
Koichi Takiguchi, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here